Sign In
Buy ADC
$76.32
-0.590 (-0.767%)
At Close: Aug 04, 2026
4 Top Dividend Stocks Yielding Around 4% to Buy Without Hesitation in April
04:46am, Tuesday, 01'st Apr 2025
Many companies have de-emphasized paying dividends over the years. That's one reason the dividend yield on the S&P 500 is only around 1.3% these days.
Agree Realty Announces $625 Million Commercial Paper Program
04:05pm, Monday, 31'st Mar 2025
ROYAL OAK, Mich. , March 31, 2025 /PRNewswire/ -- Agree Realty Corporation (NYSE: ADC) (the "Company") today announced the establishment of its inaugural commercial paper program.
Why Agree Realty Is A Buy And Hold For Retirement Income
02:39pm, Saturday, 29'th Mar 2025
New investors often aim to beat the market but should focus on downside protection, recession resiliency, and income for long-term success. Agree Realty offers stability with a strong balance sheet, h
Agree Realty: Is This Retail REIT Still A Buy After Sustained Rally? (Rating Downgrade)
11:59pm, Friday, 28'th Mar 2025
Agree Realty is paying out a 4% dividend yield, with AFFO guidance for its fiscal 2025 signalling healthy growth. There are no significant debt maturities until 2028 as ADC intends to invest at least
ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update
07:30am, Thursday, 27'th Mar 2025
Initial data from LOTIS-7 Phase 1b trial of ZYNLONTA® plus glofitamab demonstrated clinically meaningful benefit with 94% best ORR and 72% CR rate; data update expected in second quarter 2025 Complet
ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025
05:30pm, Tuesday, 25'th Mar 2025
Oral presentation to highlight preclinical investigation of Claudin-6 ADC in ovarian and NSCLC cancer models Preclinical data for PSMA and ASCT2-targeted ADCs accepted for poster presentations LAUSANN
Expression data from patient-derived xenograft (PDX) mouse models exposed to micvotabart pelidotin (MICVO) indicate gene signatures associated with efficacy, deepening understanding of MOA and potenti
ADC Therapeutics: Promise Remains, But Fortunes Rest On Success Of Single Trial In 2025
11:08pm, Monday, 24'th Mar 2025
ADC Therapeutics' primary focus is on the CD19-targeted antibody-drug conjugate Zynlonta, with key trials like LOTIS-5 and LOTIS-7 shaping its future prospects. Financially, ADCT holds $274.3 million
Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian Cancer
08:00pm, Sunday, 23'rd Mar 2025
SAN FRANCISCO and SUZHOU, China , March 23, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercia
Agree Realty: The Quality Speaks For Itself
02:47am, Sunday, 23'rd Mar 2025
Agree Realty is a top REIT investment with a 31% total return since my first coverage in 2024. ADC boasts a strong portfolio with 2,370 properties, 99.6% occupancy, and 68% rent roll from investment-g
ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on March 27, 2025
07:15am, Thursday, 20'th Mar 2025
LAUSANNE, Switzerland , March 20, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced t
Aadi Bioscience Relaunches as Whitehawk Therapeutics Marking Evolution into ADC Company
04:00pm, Tuesday, 18'th Mar 2025
New name reflects focus on accelerating portfolio of advanced ADC therapies with speed, agility and precision Upon closing of strategic transactions, cash expected to fund operations into 2028 enablin
These 5 Dividend Stocks Will Pay You Like a Boss Every Month
03:28pm, Tuesday, 18'th Mar 2025
Dividend stocks offer a reliable way to generate monthly income without the hassles of finding a side gig, buying and managing a rental property, or any other things you learn about while doom-scrolli
Dividends Come Back Into Vogue: My Favorite Places For Income Extraction
09:15am, Tuesday, 18'th Mar 2025
Currently, we have many signs pinpointing to a value factor outperforming growth. It seems that the dividend-oriented stocks might become the new glamour. In this article, I elaborate on the key reaso
Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline
04:05pm, Thursday, 13'th Mar 2025
– Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as Sutro continues to seek a partner –
